Various embodiments of the present disclosure generally relate to implantable medical devices. More specifically, embodiments of the present disclosure relate to MRI conditionally safe lead conductors.
When functioning properly, the human heart maintains its own intrinsic rhythm and is capable of pumping adequate blood throughout the body's circulatory system. However, some individuals have irregular cardiac rhythms, referred to as cardiac arrhythmias, which can result in diminished blood circulation and cardiac output. One manner of treating cardiac arrhythmias includes the use of a pulse generator (PG) such as a pacemaker, an implantable cardioverter defibrillator (ICD), or a cardiac resynchronization (CRT) device. Such devices are typically coupled to a number of conductive leads having one or more electrodes that can be used to deliver pacing therapy and/or electrical shocks to the heart. In atrioventricular (AV) pacing, for example, the leads are usually positioned in a ventricle and atrium of the heart, and are attached via lead terminal pins to a pacemaker or defibrillator which is implanted pectorally or in the abdomen.
Magnetic resonance imaging (MRI) is a non-invasive imaging procedure that utilizes nuclear magnetic resonance techniques to render images within a patient's body. Typically, MRI systems employ the use of a magnetic coil having a magnetic field strength of between about 0.2 to 3 Teslas. During the procedure, the body tissue is briefly exposed to radio frequency (RF) pulses of electromagnetic energy in a plane perpendicular to the magnetic field. The resultant electromagnetic energy from these pulses can be used to image the body tissue by measuring the relaxation properties of the excited atomic nuclei in the tissue. In some cases, imaging a patient's chest area may be clinically advantageous. In a chest MRI procedure, implanted pulse generators and leads may also be exposed to the applied electromagnetic fields.
The various embodiments of the present disclosure relate to an implantable electrical lead including a multi-layer coil conductor configured such that the lead exhibits a predetermined axial stiffness or bending stiffness.
In Example 1, an implantable electrical lead includes a lead body and a multi-layer coil conductor extending within the lead body. The multi-layer coil conductor includes a first coil layer and a second coil layer disposed about the first coil layer. The first and second coil layers are configured such that the multi-layer coil conductor has an axial stiffness substantially equal to an axial stiffness of the lead body adjacent to the multi-layer coil conductor.
In Example 2, the implantable electrical lead according to Example 1, wherein each of the first and second coil layers includes a filar having a filar thickness, a coil outside diameter, and a coil pitch, and wherein one or more of the filar thickness, the coil outside diameter, and the coil pitch are such that the axial stiffness of the multi-layer coil conductor is substantially equal to the axial stiffness of the lead body adjacent to the multi-layer coil conductor.
In Example 3, the implantable electrical lead according to either Example 1 or Example 2, wherein a filar material and a coil wind geometry of the first and second coil layers are such that the axial stiffness of the multi-layer coil conductor is substantially equal to the axial stiffness of the lead body adjacent to the multi-layer coil conductor.
In Example 4, the implantable electrical lead according to any of Examples 1-3, wherein the multi-layer coil conductor is mechanically and electrically connected to an electrode.
In Example 5, the implantable electrical lead according to any of Examples 1-4, wherein the multi-layer coil conductor is configured to allow the electrode to move axially relative to a proximal connector when under tensile load.
In Example 6, the implantable electrical lead according to any of Examples 1-5, further comprising a layer of insulating material between the first and second coil layers.
In Example 7, the implantable electrical lead according to any of Examples 1-6, wherein each filar of the first and second coil layers is individually insulated.
In Example 8, an implantable electrical lead includes a lead body having a longitudinal body lumen, an electrode coupled to the flexible body in the distal region, and a multi-layer coil conductor extending within the longitudinal body lumen and coupled to the electrode. The multi-layer coil conductor includes a first coil layer and a second coil layer disposed about the first coil layer. At least one parameter of the first and the second coil layer is configured such that the lead exhibits a predetermined axial stiffness or bending stiffness. The at least one parameter of the first and second coil layers is at least one of a coil filar thickness, a number of filars, a filar material, a coil winding direction, or a coil diameter. The first and second coil layers are configured such that the multi-layer coil conductor has an axial stiffness substantially equal to an axial stiffness of the lead body adjacent to the multi-layer coil conductor.
In Example 9, the implantable electrical lead according to Example 8, further comprising a third coil layer disposed around the second coil layer, wherein at least one parameter of the third coil layer is configured such that the lead exhibits a predetermined axial bending stiffness.
In Example 10, the implantable electrical lead according to either Example 8 or Example 9, wherein each of the first and second coil layers is formed from one or more filars of a silver core drawn filled tube (DFT) wire having an MP35N cladding.
In Example 11, the implantable electrical lead according to any of Examples 8-10, wherein the multi-layer coil conductor is mechanically and electrically connected to a second electrode coupled to the lead body.
In Example 12, the implantable electrical lead according to any of Examples 8-11, wherein the multi-layer coil conductor allows the second electrode to move axially relative to a proximal connector when under tensile load.
In Example 13, the implantable electrical lead according to any of Examples 8-12, wherein each of the filars of the first and second coil layers is individually insulated.
In Example 14, an implantable electrical lead includes a lead body and a multi-layer coil conductor extending within the lead body. The multi-layer coil conductor includes a first coil layer and a second coil layer disposed about the first coil layer. At least one parameter of the first and the second coil layer is configured such that the multi-layer coil conductor has a pre-determined spring constant along at least a portion of its length. The first and second coil layers are configured such that the multi-layer coil conductor has an axial stiffness substantially equal to an axial stiffness of the lead body adjacent to the multi-layer coil conductor.
In Example 15, the implantable electrical lead according to Example 14, wherein the pre-determined spring constant is such that the lead returns to its original length after axial elongation of the multi-layer coil conductor.
In Example 16, the implantable electrical lead according to either Example 14 or Example 15, wherein the multi-layer coil conductor is mechanically and electrically connected to an electrode coupled to the lead body.
In Example 17, the implantable electrical lead according any of Examples 14-16, wherein the multi-layer coil conductor is configured to allow the electrode to move axially relative to a proximal connector when under tensile load.
In Example 18, the implantable electrical lead according to any of Examples 14-17, wherein the multi-layer coil further comprises a third coil layer disposed around the second coil layer, wherein at least one parameter of the third coil layer is configured such that the lead exhibits a predetermined axial bending stiffness.
In Example 19, the implantable electrical lead according to any of Examples 14-18, further comprising a layer of insulating material between the first and second coil layers.
In Example 20, the implantable electrical lead according to any of Examples 14-19, wherein each filar of the first and second coil layers is individually insulated.
The drawings have not necessarily been drawn to scale. For example, the dimensions of some of the elements in the figures may be expanded or reduced to help improve the understanding of the embodiments of the present invention. While the invention is amenable to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and are described in detail below. The intention, however, is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.
As explained in further detail below, various embodiments of the present invention relate to cardiac rhythm management (CRM) systems incorporating new lead designs advantageously adapted for operation in a magnetic resonance imaging (MRI) environment. In some embodiments, the leads including conductor designs configured to provide suitable electrical performance for delivering pacing and/or defibrillation shock therapy and to minimize the lead's reaction to applied electromagnetic energy during MRI procedures.
In the following description, for the purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of embodiments of the present invention. It will be apparent, however, to one skilled in the art that embodiments of the present invention may be practiced without some of these specific details.
While, for convenience, some embodiments are described with reference to IMDs in the presence of MRI scanners, embodiments of the present invention may be applicable to various other physiological measurements, treatments, IMD devices, lead types, and other non-invasive examination techniques in which conductive leads are exposed to time varying magnetic fields. As such, the applications discussed herein are not intended to be limiting, but instead exemplary. In addition, various embodiments are applicable to all levels of sensory devices from a single IMD with a sensor to large networks of sensory devices.
Thus, in the illustrated embodiment, the PG 140 can be an implantable device such as a pacemaker, an ICD, a cardiac resynchronization therapy (CRT) device, a CRT device with defibrillation capabilities (a CRT-D device), or a comparable device. The PG 140 can be implanted subcutaneously within the body, typically at a location such as in the patient's chest. In some embodiments, PG 140 can be implanted in or near the abdomen.
The external device(s) 130 may be a local or remote terminal or other device (e.g., a computing device and/or programming device), operable to communicate with the PG 140 from a location outside of the patient's body. According to various embodiments, external device 130 can be any device external to the patient's body that is telemetry enabled and capable of communicating with the PG 140. Examples of external devices can include, but are not limited to, programmers (PRM), in-home monitoring devices, personal computers with telemetry devices, MRI scanner with a telemetry device, manufacturing test equipment, or wands. In some embodiments, the PG 140 communicates with the remote terminal 130 via a wireless communication interface. Examples of wireless communication interfaces can include, but are not limited to, radio frequency (RF), inductive, and acoustic telemetry interfaces.
The lead 150 has a flexible body 200 including a proximal region 205 and a distal region 250. As shown, the lead 150 is coupled to the PG 140, and the distal region 250 of the lead body 200 is at least partially implanted at a desired location within the right ventricle 220. As further shown, the lead 150 includes a pair of coil electrodes 255, 257 along the distal region 250, such that when implanted as shown in
Although the illustrative embodiment depicts only a single lead 150 inserted into the patient's heart 160, in other embodiments multiple leads can be utilized so as to electrically stimulate other areas of the heart 160. In some embodiments, for example, the distal portion of a second lead (not shown) may be implanted in the right atrium 210. In addition, another lead may be implanted within the coronary venous system to facilitate pacing the left ventricle, i.e., in a CRT or CRT-D system providing bi-ventricular pacing, as is known in the art. Other types of leads such as epicardial leads may also be utilized in addition to, or in lieu of, the lead 150 depicted in
During operation, the lead 150 conveys electrical signals between the heart 160 and the PG 140. For example, in those embodiments where the PG 140 has pacing capabilities, the lead 150 can be utilized to deliver electrical therapeutic stimulus for pacing the heart 160. In those embodiments where the PG 140 is an ICD, the lead 150 can be utilized to deliver high voltage electric shocks to the heart 160 via the electrodes 255, 257 in response to an event such as a ventricular fibrillation.
As explained in detail below, various embodiments of the present invention relate to new lead designs that allow for improved mechanical characteristics and safe operation in an MRI environment. In some embodiments, traditional conductor cables are replaced with low profile multi-layer coil conductors. The multi-layer coil conductors allow lead designers to maintain a small lead profile in pace/sense lead applications while better controlling axial elongation of the lead under tensile load.
The ZI parameter 270 in the circuit 260 represents the equivalent impedance exhibited by the lead 150 at the RF frequency of the MRI scanner. The impedance value ZI 270 may represent, for example, the inductance or the equivalent impedance resulting from the parallel inductance and the coil turn by turn capacitance exhibited by the lead 150 at an RF frequency of 64 MHz for a 1.5 Tesla MRI scanner, or at an RF frequency of 128 MHz for a 3 Tesla MRI scanner. The impedance ZI of the lead 150 is a complex quantity having a real part (i.e., resistance) and an imaginary part (i.e., reactance).
Zb 275 in the circuit 260 may represent the impedance of the body tissue at the point of lead contact. Zc 280, in turn, may represent the capacitive coupling of the lead 150 to surrounding body tissue along the length of the lead 150, which may provide a path for the high frequency current (energy) to leak into the surrounding tissue at the RF frequency of the MRI scanner. Minimizing the absorbed energy (represented by source Vi 265) reduces the energy that is transferred to the body tissue at the point of lead contact with the body tissue.
As can be further seen in
Vb=Vi Zbe/(Zbe+ZI), where Zbe=Zb in parallel with Zc.
The temperature at the tip of the lead 150 where contact is typically made to the surrounding tissue is related in part to the power dissipated at 275 (i.e., at “Zb”), which, in turn, is related to the square of Vb. To minimize temperature rises resulting from the power dissipated at 275, it is thus desirable to minimize Vi (265) and Zc (280) while also maximizing the impedance ZI (270) of the lead 150. In some embodiments, the impedance ZI (270) of the lead 150 can be increased at the RF frequency of the MRI scanner, which aids in reducing the energy dissipated into the surrounding body tissue at the point of contact 275.
In the various embodiments described in further detail below, the impedance of the lead 150 can be increased by adding inductance to the lead 150 and/or by a suitable construction technique. For example, in various embodiments, the inductance of the lead 150 is increased by selectively configuring the conductors used to supply electrical energy to the electrodes 255, 257.
In the illustrated embodiment, the connector assembly 310 includes a connector body 320 and a terminal pin 325. The connector assembly 310 is coupled to the lead body 200 and can be configured to mechanically and electrically couple the lead to a header on PG 140 (see
In various embodiments, the tip electrode 312 is in the form of an electrically active fixation helix at the distal end of the lead 150. In some embodiments, the tip electrode 312 can be an extendable/retractable helix supported by a mechanism to facilitate longitudinal translation of the helix relative to the lead body as the helix is rotated. In those embodiments, the terminal pin 325 may be rotatable relative to the connector body 320 and the lead body 200 such that rotation of the terminal pin 325 relative to the lead body 200 causes the inner conductor, and in turn, the helical tip electrode to rotate and translate longitudinally relative to the lead body 200. Various mechanisms and techniques for providing extendable/retractable fixation helix assemblies (both electrically active and passive) are known to those of ordinary skill in the art, and need not be described in greater detail here.
The pace/sense electrode (whether a solid tip electrode as described above or an active-fixation helix such as shown in
The coil electrodes 255, 257 can take on any configuration suitable for delivering a relatively high-voltage therapeutic shock to the heart for defibrillation therapy. In various embodiments, the coil electrodes 255, 257 can be made from any suitable electrically conductive material such as those discussed in the preceding paragraph. The lead 150 also includes a conductor (not shown in
In
In some embodiments, the lead body 200 does not include separate, coaxial tubular members, but instead, includes only a single tubular member (e.g., the member 380) including one or more longitudinal lumens for housing the requisite conductors. For illustrative purposes, the three lumens 390, 395, 400 of the inner tubular member 380 are shown having different diameters. In other embodiments, however, the relative dimensions and/or locations of the lumens 390, 395, 400 may vary from that shown. In addition, the inner tubular member 380 may include a greater or lesser number of lumens, depending on the particular configuration of the lead 150. For example, the inner tubular member 380 may include a greater number of lumens to house additional conductor wires and/or electrode coils within the lead 150 for supplying current to other shocking coils and/or pace/sense electrodes.
In the illustrated embodiment, the conductor 410 is a single layer coil conductor such as would be used in conjunction with a conventional, low-voltage pace/sense electrode, e.g., the tip electrode 312. In some embodiments, for example, the coil conductor 410 is configured to have a relatively high impedance when exposed to electromagnetic energy such as that present during an MRI scan. In various such embodiments, the coil conductor 410 is configured according to the various embodiments described, for example, in U.S. Patent Application Publication No. 2009/0198314, which is incorporated herein by reference in its entirety. The increased impedance aids in reducing the energy dissipated into the surrounding body tissue at or near the lead electrode(s). In various embodiments, the conductor 410 and the lumen 390 are omitted.
As explained in further detail below, the conductors 415 and 420 are multi-layer conductor assemblies incorporated into the lead 150 to provide a conditionally-safe MRI-compatible lead design, as well as to provide improved fatigue resistance and other mechanical properties during delivery and under chronic operating conditions. In various embodiments, the multi-layer coil conductors 415, 420 include multiple coil layers having selectively controlled coil properties (e.g., pitch, outside diameter, filar thickness, etc.) to make a highly inductive, highly conductive, small diameter conductor that has suitable mechanical characteristics for a stimulation/sensing lead body.
In the illustrated embodiment, the coil conductor 415 is a three-layer conductor and the coil conductor 420 is a two-layer conductor. In various embodiments, multi-layer coil conductors utilizing more than three coil layers can be utilized. In various embodiments, the single layer coil conductor 410 can be replaced with a multi-layer coil conductor similar or identical to the coil conductor 415 and/or 420.
In some embodiments, the outer layer 422 of the coil conductor 420 can be wound to coil diameter Do of less than about 0.013 inches. In some embodiments, the outer layer is close pitched and can have one or more filars having a maximum filar thickness of about 0.004 inches. In accordance with various embodiments, the outer layer may or may not be present depending on the desired application of the lead. For example, in some cases, the outer layer may be used to change the resistance of the multi-layer coil conductor 420. In at least one embodiment, the outer layer 422 may have a filar thickness of from about 0.001 to about 0.004 inches.
The middle layer 425 of the coil conductor 420 is close pitched and can be wound to a coil diameter Dm less than the inner diameter of the outer coil layer 422. In some embodiments, the middle layer can have one or more filars having a maximum filar thickness of from about 0.0007 to about 0.003 inches.
The inner coil layer 430 of the coil conductor 420 is close pitched and can be wound to a coil diameter Di less than the inner diameter of the middle layer 425. In some embodiments, the inner layer can have one or more filars having a maximum filar thickness of from about 0.0007 to about 0.001 inches.
Of course, in various other embodiments, multi-layer coil conductor 420 utilizes different ranges of dimensions and other parameters (e.g., filar count) of the respective coil layers 422, 425, 430 depending on the operational needs for the lead 150.
In the various embodiments, the filar material can be any suitable material exhibiting the desired electrical and mechanical properties. In one embodiment, the filars of the outer, middle, and/or inner coil layers 422, 425, 430 are made of drawn filled tube (DFT) wire including a silver core (about 40%) with an MP35N or tantalum cladding. In another embodiment, the outer, middle, and/or inner coil layers 422, 425, 430 are made of DFT wire including a tantalum core with a MP35N cladding. The coil layers 422, 425, 430 may be comprised of the same or different materials, and each of the coil layers 422, 425, 430 may include different silver fill levels.
In various embodiments, the filars of each layer of the coil conductor 420 are wound in the same pitch direction. That is, the individual filars of each coil layer are wound to have either a right-hand pitch or a left-hand pitch when viewing the coil along its longitudinal axis.
In various embodiments, one or more of the coil layers 422, 425, 430 has a variable coil pitch along its length, which operates to de-tune the coil conductor 420 to reduce the effect of externally applied electromagnetic radiation (i.e., due to an MRI chest scan).
In various embodiments, the individual coil layers 422, 425 and 430 can be separately optimized to each exhibit a different inductance, e.g., by modifying the filar thickness, pitch, and/or coil layer diameter, to further modify the performance of the lead 150 under MRI conditions.
Some embodiments of the present invention include one or more layers of insulation between one or more of the adjacent coil layers 422, 425 or 430. Alternatively, or additionally, in various embodiments, the individual filars or the coil layers 422, 425, and/or 430 are individually insulated. Any suitable insulation material can be utilized, if desired. Exemplary insulating materials for the filars and/or between the coil layers include ethylene tetrafluoroethylene (ETFE), polytetrafluoroethylene (PTFE), expanded PTFE (ePTFE), silicone, and the copolymers of the foregoing.
The various embodiments of the lead 150 described above, advantageously minimize induced currents in the lead conductors resulting from exposure to external MRI electromagnetic fields. This is in contrast to conventional lead systems utilizing stranded cable conductors to transmit the shocking currents from the PG to the shocking electrodes. While such cable conductors provide excellent electrical performance for delivering anti-tachycardia therapy, stranded cable conductors also have a low impedance and thus are susceptible to generation of induced currents when exposed to an alternating electromagnetic field such as that present during an MRI scan. Various embodiments of the present invention can result in lead 150 exhibiting a temperature rise when exposed to MRI radiation of approximately half that experienced utilizing traditional high energy cables which are conventionally utilized to supply energy to high-voltage shocking coils in defibrillation leads. The high impedance conductor configurations for the lead 150 described above minimize the effects of MRI radiation while still providing suitable electrical performance for use in anti-tachycardia therapy applications.
In addition, In accordance with some embodiments, the design parameters of the multi-layer coil conductors can be tuned to control the mechanical properties, e.g., effective spring constant and thus stiffness of the overall lead assembly, bending stiffness, and the like. Such tuning may enable the user minimize stresses (loads) on adjacent (distal) polymer components, minimize the potential for shear bond failure, facilitate/control the lead bias shape, and minimize the impact of axial length tolerance stack-up during assembly, in both low and high voltage lead applications. For example, in various embodiments, the shocking coils 255, 257 (see
In various embodiments, the multi-layer coil conductor 415 and/or 420 can be tuned to control the effective spring constant (expressed in force per unit length) of the coil conductor 415 and/or 420 so as to reduce or eliminate the difference in axial stiffness between the conductor coil and the adjacent insulating elements (i.e., lead body 200 components). By controlling and optimizing the coil conductor spring constant/axial stiffness in this way, the overall axial strength of the polymeric lead body components can be maintained, for example, where the coil conductor 415, 420 terminates proximal to the lead body component. Additionally, by reducing or eliminating large differences in the axial stiffness of the conductors (i.e., by utilizing the multi-layer coil conductors 415 and/or 420) and the parallel polymeric lead body components, shear forces between these elements are advantageously reduced. Utilizing the multi-layer coil conductors 415, 420 in lieu of conductor cables also eliminates snaking of the conductor that can result due to the contraction and release of a tensile axial load on the conductor.
Exemplary design parameters that can be varied to tune/optimize the mechanical characteristics discussed above can include, without limitation, the selection of conductor materials, number of layers, wind geometry, pitch, filar diameter, number of filars, and others.
In addition to the coil conductor configurations described above, the various embodiments of the lead 150 of the present invention may optionally incorporate other features or techniques to minimize the effects of MRI radiation. For example, in some embodiments, shielding may be added to the lead 150 to further reduce the amount of electromagnetic energy picked up from the lead 150. For example, the energy picked up from the shielding can be coupled to the patient's body along the length of the lead 150, preventing the energy from coupling to the lead tip. The transfer of intercepted energy by the shielding along the length of the shielding/lead can also be inhibited by dissipating the energy as resistive loss, using resistive material for the shielding construction.
Various modifications and additions can be made to the exemplary embodiments discussed without departing from the scope of the present invention. For example, while the embodiments described above refer to particular features, the scope of this invention also includes embodiments having different combinations of features and embodiments that do not include all of the described features. Accordingly, the scope of the present invention is intended to embrace all such alternatives, modifications, and variations as fall within the scope of the claims, together with all equivalents thereof.
This application is a continuation of U.S. application Ser. No. 13/767,445, filed Feb. 14, 2013, is now U.S. Pat. No. 8,676,351 which is a continuation of U.S. application Ser. No. 12/940,489, filed Nov. 5, 2010, is now U.S. Pat. No. 8,391,994 and claims the benefit of U.S. Provisional Application 61/291,556, filed Dec. 31, 2009, all of which are herein incorporated by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
3614692 | Rozelle et al. | Oct 1971 | A |
4131759 | Felkel | Dec 1978 | A |
4135518 | Dutcher | Jan 1979 | A |
4146036 | Benjamin et al. | Mar 1979 | A |
4209019 | Dutcher et al. | Jun 1980 | A |
4253462 | Dutcher et al. | Mar 1981 | A |
4350169 | Dutcher et al. | Sep 1982 | A |
4381013 | Dutcher | Apr 1983 | A |
4404125 | Abolins et al. | Sep 1983 | A |
4437474 | Peers-Trevarton | Mar 1984 | A |
4484586 | McMickle et al. | Nov 1984 | A |
4493329 | Crawford et al. | Jan 1985 | A |
4574800 | Peers-Trevarton | Mar 1986 | A |
4643202 | Roche | Feb 1987 | A |
4649938 | McArthur | Mar 1987 | A |
4869970 | Gulla et al. | Sep 1989 | A |
5002067 | Berthelsen et al. | Mar 1991 | A |
5003975 | Hafelfinger et al. | Apr 1991 | A |
5020545 | Soukup | Jun 1991 | A |
5056516 | Spehr | Oct 1991 | A |
5074313 | Dahl et al. | Dec 1991 | A |
5144960 | Mehra et al. | Sep 1992 | A |
5201865 | Kuehn | Apr 1993 | A |
5217010 | Tsitlik et al. | Jun 1993 | A |
5222506 | Patrick et al. | Jun 1993 | A |
5231996 | Bardy et al. | Aug 1993 | A |
5241957 | Camps et al. | Sep 1993 | A |
5243911 | Dow et al. | Sep 1993 | A |
5246014 | Williams et al. | Sep 1993 | A |
5259395 | Li | Nov 1993 | A |
5300108 | Rebell et al. | Apr 1994 | A |
5324322 | Grill, Jr. et al. | Jun 1994 | A |
5330522 | Kreyenhagen | Jul 1994 | A |
5354327 | Smits | Oct 1994 | A |
5370666 | Lindberg et al. | Dec 1994 | A |
5378234 | Hammerslag et al. | Jan 1995 | A |
5387199 | Siman et al. | Feb 1995 | A |
5417208 | Winkler | May 1995 | A |
5425755 | Doan | Jun 1995 | A |
5456707 | Giele | Oct 1995 | A |
5476485 | Weinberg et al. | Dec 1995 | A |
5483022 | Mar | Jan 1996 | A |
5522872 | Hoff | Jun 1996 | A |
5522875 | Gates et al. | Jun 1996 | A |
5534018 | Wahlstrand et al. | Jul 1996 | A |
5542173 | Mar et al. | Aug 1996 | A |
5545205 | Schulte et al. | Aug 1996 | A |
5549646 | Katz et al. | Aug 1996 | A |
5554139 | Okajima | Sep 1996 | A |
5574249 | Lindsay | Nov 1996 | A |
5584873 | Shoberg et al. | Dec 1996 | A |
5599576 | Opolski | Feb 1997 | A |
5609622 | Soukup et al. | Mar 1997 | A |
5618208 | Crouse et al. | Apr 1997 | A |
5727552 | Ryan | Mar 1998 | A |
5727553 | Saad | Mar 1998 | A |
5728149 | Laske et al. | Mar 1998 | A |
5755742 | Schuelke et al. | May 1998 | A |
5760341 | Laske et al. | Jun 1998 | A |
5766227 | Nappholz et al. | Jun 1998 | A |
5800496 | Swoyer et al. | Sep 1998 | A |
5810887 | Accorti, Jr. et al. | Sep 1998 | A |
5817136 | Nappholz et al. | Oct 1998 | A |
5824026 | Diaz | Oct 1998 | A |
5833715 | Vachon et al. | Nov 1998 | A |
5849031 | Martinez et al. | Dec 1998 | A |
5891114 | Chien et al. | Apr 1999 | A |
5891179 | Er et al. | Apr 1999 | A |
5935159 | Cross, Jr. et al. | Aug 1999 | A |
5957966 | Schroeppel et al. | Sep 1999 | A |
5957970 | Shoberg et al. | Sep 1999 | A |
5968087 | Hess et al. | Oct 1999 | A |
6016447 | Juran et al. | Jan 2000 | A |
6057031 | Breme et al. | May 2000 | A |
6078840 | Stokes | Jun 2000 | A |
6083216 | Fischer, Sr. | Jul 2000 | A |
6101417 | Vogel et al. | Aug 2000 | A |
6106522 | Fleischman et al. | Aug 2000 | A |
6141593 | Patag | Oct 2000 | A |
6143013 | Samson et al. | Nov 2000 | A |
6178355 | Williams et al. | Jan 2001 | B1 |
6192280 | Sommer et al. | Feb 2001 | B1 |
6208881 | Champeau | Mar 2001 | B1 |
6249708 | Nelson et al. | Jun 2001 | B1 |
6256541 | Heil et al. | Jul 2001 | B1 |
6259954 | Conger et al. | Jul 2001 | B1 |
6289250 | Tsuboi et al. | Sep 2001 | B1 |
6295476 | Schaenzer | Sep 2001 | B1 |
6304784 | Allee et al. | Oct 2001 | B1 |
6317633 | Jorgenson et al. | Nov 2001 | B1 |
6360129 | Ley et al. | Mar 2002 | B1 |
6400992 | Borgersen et al. | Jun 2002 | B1 |
6428537 | Swanson et al. | Aug 2002 | B1 |
6434430 | Borgersen et al. | Aug 2002 | B2 |
6456888 | Skinner et al. | Sep 2002 | B1 |
6493591 | Stokes | Dec 2002 | B1 |
6501991 | Honeck et al. | Dec 2002 | B1 |
6501994 | Janke et al. | Dec 2002 | B1 |
6510345 | Van Bentem | Jan 2003 | B1 |
6516230 | Williams et al. | Feb 2003 | B2 |
6526321 | Spehr | Feb 2003 | B1 |
6564107 | Bodner et al. | May 2003 | B1 |
6671554 | Gibson et al. | Dec 2003 | B2 |
6701191 | Schell | Mar 2004 | B2 |
6721600 | Jorgenson et al. | Apr 2004 | B2 |
6721604 | Robinson et al. | Apr 2004 | B1 |
6813521 | Bischoff et al. | Nov 2004 | B2 |
6850803 | Jimenez et al. | Feb 2005 | B1 |
6854994 | Stein et al. | Feb 2005 | B2 |
6866044 | Bardy et al. | Mar 2005 | B2 |
6906256 | Wang | Jun 2005 | B1 |
6920361 | Williams | Jul 2005 | B2 |
6925334 | Salys | Aug 2005 | B1 |
6944489 | Zeijlemaker et al. | Sep 2005 | B2 |
6949929 | Gray et al. | Sep 2005 | B2 |
6978185 | Osypka | Dec 2005 | B2 |
6985755 | Cadieux et al. | Jan 2006 | B2 |
6985775 | Reinke et al. | Jan 2006 | B2 |
6993373 | Vrijheid et al. | Jan 2006 | B2 |
6999818 | Stevenson et al. | Feb 2006 | B2 |
6999821 | Jenney et al. | Feb 2006 | B2 |
7013180 | Dublin et al. | Mar 2006 | B2 |
7013182 | Krishnan | Mar 2006 | B1 |
7047075 | Stubbs | May 2006 | B2 |
7047083 | Gunderson et al. | May 2006 | B2 |
7050855 | Zeijlemaker et al. | May 2006 | B2 |
7113827 | Silvestri et al. | Sep 2006 | B2 |
7123013 | Gray | Oct 2006 | B2 |
7127294 | Wang et al. | Oct 2006 | B1 |
7135978 | Gisselberg et al. | Nov 2006 | B2 |
7138582 | Lessar et al. | Nov 2006 | B2 |
7158837 | Osypka et al. | Jan 2007 | B2 |
7174219 | Wahlstrand et al. | Feb 2007 | B2 |
7174220 | Chitre et al. | Feb 2007 | B1 |
7205768 | Schulz et al. | Apr 2007 | B2 |
7239916 | Thompson et al. | Jul 2007 | B2 |
7242987 | Holleman et al. | Jul 2007 | B2 |
7257449 | Bodner | Aug 2007 | B2 |
7289851 | Gunderson et al. | Oct 2007 | B2 |
7363090 | Halperin et al. | Apr 2008 | B2 |
7369898 | Kroll et al. | May 2008 | B1 |
7378931 | Odahara et al. | May 2008 | B2 |
7388378 | Gray et al. | Jun 2008 | B2 |
7389148 | Morgan | Jun 2008 | B1 |
7453344 | Maeda et al. | Nov 2008 | B2 |
7535363 | Gisselberg et al. | May 2009 | B2 |
7571010 | Zarembo et al. | Aug 2009 | B2 |
7610101 | Wedan et al. | Oct 2009 | B2 |
7630761 | Salo et al. | Dec 2009 | B2 |
7689291 | Polkinghorne et al. | Mar 2010 | B2 |
7765005 | Stevenson | Jul 2010 | B2 |
7853332 | Olsen et al. | Dec 2010 | B2 |
7877150 | Hoegh et al. | Jan 2011 | B2 |
7912552 | Przybyszewski | Mar 2011 | B2 |
7917213 | Bulkes et al. | Mar 2011 | B2 |
7933662 | Marshall et al. | Apr 2011 | B2 |
7953499 | Knapp et al. | May 2011 | B2 |
7986999 | Wedan et al. | Jul 2011 | B2 |
7991484 | Sengupta et al. | Aug 2011 | B1 |
8000801 | Stevenson et al. | Aug 2011 | B2 |
8027736 | Wahlstrand et al. | Sep 2011 | B2 |
8032230 | Cox et al. | Oct 2011 | B1 |
8046084 | Bodner | Oct 2011 | B2 |
8099177 | Dahlberg | Jan 2012 | B2 |
8103360 | Foster | Jan 2012 | B2 |
8108054 | Helland | Jan 2012 | B2 |
8145324 | Stevenson et al. | Mar 2012 | B1 |
8170688 | Wedan et al. | May 2012 | B2 |
8200342 | Stevenson et al. | Jun 2012 | B2 |
8214055 | Erickson | Jul 2012 | B2 |
8244346 | Foster et al. | Aug 2012 | B2 |
8255055 | Ameri | Aug 2012 | B2 |
8306630 | Stubbs et al. | Nov 2012 | B2 |
8315715 | Erickson | Nov 2012 | B2 |
8332050 | Perrey et al. | Dec 2012 | B2 |
8335572 | Ameri | Dec 2012 | B2 |
8391994 | Foster et al. | Mar 2013 | B2 |
8401671 | Wedan et al. | Mar 2013 | B2 |
8543209 | Tyers et al. | Sep 2013 | B2 |
8543218 | Erickson | Sep 2013 | B2 |
8666508 | Foster et al. | Mar 2014 | B2 |
8666512 | Walker et al. | Mar 2014 | B2 |
8670828 | Hall et al. | Mar 2014 | B2 |
8670840 | Wedan et al. | Mar 2014 | B2 |
8676344 | Desai et al. | Mar 2014 | B2 |
8676351 | Foster et al. | Mar 2014 | B2 |
8682451 | Wengreen et al. | Mar 2014 | B2 |
8688236 | Foster | Apr 2014 | B2 |
8731685 | Ameri | May 2014 | B2 |
8744600 | Perrey et al. | Jun 2014 | B2 |
8798767 | Foster et al. | Aug 2014 | B2 |
8825179 | Walker et al. | Sep 2014 | B2 |
8825181 | Foster et al. | Sep 2014 | B2 |
20020065544 | Smits | May 2002 | A1 |
20020072769 | Silvian et al. | Jun 2002 | A1 |
20020111664 | Bartig et al. | Aug 2002 | A1 |
20020128689 | Connelly et al. | Sep 2002 | A1 |
20020144720 | Zahorik et al. | Oct 2002 | A1 |
20030028231 | Partridge et al. | Feb 2003 | A1 |
20030050680 | Gibson et al. | Mar 2003 | A1 |
20030083723 | Wilkinson et al. | May 2003 | A1 |
20030083726 | Zeijlemaker et al. | May 2003 | A1 |
20030092303 | Osypka | May 2003 | A1 |
20030093136 | Osypka et al. | May 2003 | A1 |
20030093138 | Osypka et al. | May 2003 | A1 |
20030139794 | Jenney et al. | Jul 2003 | A1 |
20030140931 | Zeijlemaker et al. | Jul 2003 | A1 |
20030144705 | Funke | Jul 2003 | A1 |
20030144716 | Reinke et al. | Jul 2003 | A1 |
20030144718 | Zeijlemaker | Jul 2003 | A1 |
20030144719 | Zeijlemaker | Jul 2003 | A1 |
20030144720 | Villaseca et al. | Jul 2003 | A1 |
20030144721 | Villaseca et al. | Jul 2003 | A1 |
20030204217 | Greatbatch | Oct 2003 | A1 |
20040014355 | Osypka et al. | Jan 2004 | A1 |
20040064161 | Gunderson et al. | Apr 2004 | A1 |
20040064173 | Hine et al. | Apr 2004 | A1 |
20040064174 | Belden | Apr 2004 | A1 |
20040088033 | Smits et al. | May 2004 | A1 |
20040097965 | Gardeski et al. | May 2004 | A1 |
20040122490 | Reinke et al. | Jun 2004 | A1 |
20040153049 | Hewitt et al. | Aug 2004 | A1 |
20040162600 | Williams | Aug 2004 | A1 |
20040167442 | Shireman et al. | Aug 2004 | A1 |
20040172117 | Hill et al. | Sep 2004 | A1 |
20040193140 | Griffin et al. | Sep 2004 | A1 |
20040243210 | Morgan et al. | Dec 2004 | A1 |
20040267107 | Lessar et al. | Dec 2004 | A1 |
20050070972 | Wahlstrand et al. | Mar 2005 | A1 |
20050090886 | MacDonald et al. | Apr 2005 | A1 |
20050113676 | Weiner et al. | May 2005 | A1 |
20050113873 | Weiner et al. | May 2005 | A1 |
20050113876 | Weiner et al. | May 2005 | A1 |
20050136385 | Mann et al. | Jun 2005 | A1 |
20050177135 | Hildebrand et al. | Aug 2005 | A1 |
20050182471 | Wang | Aug 2005 | A1 |
20050197677 | Stevenson | Sep 2005 | A1 |
20050222642 | Przybyszewski et al. | Oct 2005 | A1 |
20050222656 | Wahlstrand et al. | Oct 2005 | A1 |
20050222657 | Wahlstrand et al. | Oct 2005 | A1 |
20050222658 | Hoegh et al. | Oct 2005 | A1 |
20050222659 | Olsen et al. | Oct 2005 | A1 |
20050246007 | Sommer et al. | Nov 2005 | A1 |
20050267556 | Shuros et al. | Dec 2005 | A1 |
20050272280 | Osypka | Dec 2005 | A1 |
20050283167 | Gray | Dec 2005 | A1 |
20060009819 | Przybyszewski | Jan 2006 | A1 |
20060030774 | Gray et al. | Feb 2006 | A1 |
20060037461 | Yasumura | Feb 2006 | A1 |
20060041293 | Mehdizadeh et al. | Feb 2006 | A1 |
20060041294 | Gray | Feb 2006 | A1 |
20060041296 | Bauer et al. | Feb 2006 | A1 |
20060089691 | Kaplan et al. | Apr 2006 | A1 |
20060089695 | Bolea et al. | Apr 2006 | A1 |
20060089696 | Olsen et al. | Apr 2006 | A1 |
20060106442 | Richardson et al. | May 2006 | A1 |
20060118758 | Wang et al. | Jun 2006 | A1 |
20060129043 | Ben-Jacob et al. | Jun 2006 | A1 |
20060167536 | Nygren et al. | Jul 2006 | A1 |
20060200218 | Wahlstrand | Sep 2006 | A1 |
20060229693 | Bauer et al. | Oct 2006 | A1 |
20060247747 | Olsen et al. | Nov 2006 | A1 |
20060247748 | Wahlstrand et al. | Nov 2006 | A1 |
20060252314 | Atalar et al. | Nov 2006 | A1 |
20060253180 | Zarembo et al. | Nov 2006 | A1 |
20060271138 | MacDonald | Nov 2006 | A1 |
20060293737 | Krishnan | Dec 2006 | A1 |
20070010702 | Wang et al. | Jan 2007 | A1 |
20070027532 | Wang et al. | Feb 2007 | A1 |
20070106332 | Denker et al. | May 2007 | A1 |
20070112398 | Stevenson et al. | May 2007 | A1 |
20070156205 | Larson et al. | Jul 2007 | A1 |
20070179577 | Marshall et al. | Aug 2007 | A1 |
20070179582 | Marshall et al. | Aug 2007 | A1 |
20070191914 | Stessman | Aug 2007 | A1 |
20070208383 | Williams | Sep 2007 | A1 |
20070255378 | Polkinghorne et al. | Nov 2007 | A1 |
20080009905 | Zeijlemaker | Jan 2008 | A1 |
20080033497 | Bulkes et al. | Feb 2008 | A1 |
20080039709 | Karmarkar | Feb 2008 | A1 |
20080049376 | Stevenson et al. | Feb 2008 | A1 |
20080051854 | Bulkes et al. | Feb 2008 | A1 |
20080057784 | Zarembo et al. | Mar 2008 | A1 |
20080058902 | Gray et al. | Mar 2008 | A1 |
20080119917 | Geistert | May 2008 | A1 |
20080125754 | Beer et al. | May 2008 | A1 |
20080129435 | Gray | Jun 2008 | A1 |
20080132985 | Wedan et al. | Jun 2008 | A1 |
20080132986 | Gray et al. | Jun 2008 | A1 |
20080140152 | Imran et al. | Jun 2008 | A1 |
20080154348 | Atalar et al. | Jun 2008 | A1 |
20080208290 | Phillips et al. | Aug 2008 | A1 |
20080243218 | Bottomley et al. | Oct 2008 | A1 |
20080262584 | Bottomley et al. | Oct 2008 | A1 |
20080269831 | Erickson | Oct 2008 | A1 |
20090005825 | MacDonald | Jan 2009 | A1 |
20090024180 | Kisker et al. | Jan 2009 | A1 |
20090024197 | Jensen | Jan 2009 | A1 |
20090099440 | Viohl | Apr 2009 | A1 |
20090099555 | Viohl et al. | Apr 2009 | A1 |
20090118610 | Karmarkar et al. | May 2009 | A1 |
20090149920 | Li et al. | Jun 2009 | A1 |
20090149933 | Ameri | Jun 2009 | A1 |
20090149934 | Ameri et al. | Jun 2009 | A1 |
20090198314 | Foster et al. | Aug 2009 | A1 |
20090204171 | Ameri | Aug 2009 | A1 |
20090210022 | Powers | Aug 2009 | A1 |
20090270948 | Nghiem et al. | Oct 2009 | A1 |
20090270956 | Vase et al. | Oct 2009 | A1 |
20090281608 | Foster | Nov 2009 | A1 |
20100010602 | Wedan et al. | Jan 2010 | A1 |
20100016935 | Strandberg et al. | Jan 2010 | A1 |
20100103215 | Iriguchi | Apr 2010 | A1 |
20100106215 | Stubbs et al. | Apr 2010 | A1 |
20100114277 | Zhao et al. | May 2010 | A1 |
20100125320 | Polkinghorne et al. | May 2010 | A1 |
20100137928 | Duncan et al. | Jun 2010 | A1 |
20100174348 | Bulkes et al. | Jul 2010 | A1 |
20100174349 | Stevenson et al. | Jul 2010 | A1 |
20100234929 | Scheuermann | Sep 2010 | A1 |
20100249892 | Bulkes et al. | Sep 2010 | A1 |
20100292744 | Hill et al. | Nov 2010 | A1 |
20100331936 | Perrey et al. | Dec 2010 | A1 |
20110060394 | Poore | Mar 2011 | A1 |
20110079423 | Zhao et al. | Apr 2011 | A1 |
20110087299 | Ameri | Apr 2011 | A1 |
20110087302 | Ameri | Apr 2011 | A1 |
20110093054 | Ameri | Apr 2011 | A1 |
20110160805 | Erbstoeszer et al. | Jun 2011 | A1 |
20110160816 | Stubbs et al. | Jun 2011 | A1 |
20110160817 | Foster et al. | Jun 2011 | A1 |
20110160818 | Struve | Jun 2011 | A1 |
20110160828 | Foster et al. | Jun 2011 | A1 |
20110160829 | Foster et al. | Jun 2011 | A1 |
20110208280 | Li et al. | Aug 2011 | A1 |
20110218422 | Atalar et al. | Sep 2011 | A1 |
20110238146 | Wedan et al. | Sep 2011 | A1 |
20110288403 | Kondabatni et al. | Nov 2011 | A1 |
20120016451 | Struve et al. | Jan 2012 | A1 |
20120022356 | Olsen et al. | Jan 2012 | A1 |
20120035698 | Johnson et al. | Feb 2012 | A1 |
20120053662 | Foster et al. | Mar 2012 | A1 |
20120109270 | Foster | May 2012 | A1 |
20120143273 | Stubbs et al. | Jun 2012 | A1 |
20120161901 | Stevenson et al. | Jun 2012 | A1 |
20120179233 | Wedan et al. | Jul 2012 | A1 |
20120253340 | Stevenson et al. | Oct 2012 | A1 |
20120271394 | Foster et al. | Oct 2012 | A1 |
20130116764 | Walker et al. | May 2013 | A1 |
20130158641 | Foster et al. | Jun 2013 | A1 |
20130190849 | Perrey et al. | Jul 2013 | A1 |
20130190850 | Wedan et al. | Jul 2013 | A1 |
20130282093 | Walker et al. | Oct 2013 | A1 |
20130325093 | Foster | Dec 2013 | A1 |
20140067030 | Walker et al. | Mar 2014 | A1 |
20140114383 | Foster et al. | Apr 2014 | A1 |
20140324139 | Foster et al. | Oct 2014 | A1 |
Number | Date | Country |
---|---|---|
1762510 | Apr 2006 | CN |
1905789 | Jan 2007 | CN |
101039619 | Sep 2007 | CN |
0897997 | Feb 2003 | EP |
1594564 | Nov 2005 | EP |
1852810 | Nov 2007 | EP |
2004141679 | May 2004 | JP |
2005501673 | Jan 2005 | JP |
2005515852 | Jun 2005 | JP |
2005515854 | Jun 2005 | JP |
WO9606655 | Mar 1996 | WO |
WO03063946 | Aug 2003 | WO |
WO03063953 | Aug 2003 | WO |
WO03089045 | Oct 2003 | WO |
WO2004073791 | Sep 2004 | WO |
WO2005030322 | Apr 2005 | WO |
WO2006105066 | Mar 2006 | WO |
WO2006093685 | Sep 2006 | WO |
WO2007047966 | Apr 2007 | WO |
WO2007089986 | Aug 2007 | WO |
WO2007118194 | Oct 2007 | WO |
WO2008051122 | May 2008 | WO |
WO2009137186 | Nov 2009 | WO |
WO2010078552 | Jul 2010 | WO |
Entry |
---|
Third Party Submission Under 37 CFR 1.290 filed in U.S. Appl. No. 14/056,746 on May 20, 2014, 13 pages. |
“High Voltage Engineering and Testing, 2nd Edition”, edited by Hugh M. Ryan, Institution of Engineering and Technology, 2001, 15 pages. |
Avalanche Breakdown, Wikipedia Article, captured Apr. 6, 2010, [http://en.wikipedia.org/wiki/Avalanche—breakdown]. |
Basso, Christophe, “SPICE Model Simulates Spark-Gap Arrestor”, Electronics Design, Strategy, and News (EDN), Jul. 3, 1997, 4 pages. |
Citel Inc., Data Sheet, BH Series 2 Electrode Miniature Gas Discharge Tube Surge Arrester—8mm, May 14, 2009, 2 pages. |
File History for U.S. Appl. No. 11/015,807, filed Dec. 17, 2004. |
Gray, Robert W. et al., “Simple design changes to wires to substantially reduce MRI-induced heating at 1.5 T: implications for implanted leads”, Magnetic Resonance Imaging 23 (2005) 887-891. |
Hayes, David L., Chapter 4, “Generator and Lead Selection” from book entitled “Cardiac Pacing and Defibrillation A Clinical Approach”, John Wiley & Sons, (c) 2000 Mayo Foundation, p. 129-157. |
International Search Report and Written Opinion issued in PCT/US2008/085518 on Oct. 29, 2009, 15 pages. |
International Search Report and Written Opinion issued in PCT/US2009/032838, mailed May 4, 2009, 14 pages. |
International Search Report and Written Opinion issued in PCT/US2009/038629, mailed Jun. 29, 2009, 11 pages. |
International Search Report and Written Opinion issued in PCT/US2009/056843, mailed Dec. 29, 2009, 13 pages. |
International Search Report and Written Opinion issued in PCT/US2010/024062, mailed Sep. 27, 2010. |
International Search Report and Written Opinion issued in PCT/US2010/033686 on Aug. 10, 2010, 12 pages. |
International Search Report and Written Opinion issued in PCT/US2010/048620, mailed Apr. 5, 2011, 10 pages. |
International Search Report and Written Opinion issued in PCT/US2010/053223, mailed Dec. 27, 2010, 11 pages. |
International Search Report and Written Opinion issued in PCT/US2010/055130, mailed Mar. 10, 2011, 11 pages. |
International Search Report and Written Opinion issued in PCT/US2010/055653, mailed Feb. 1, 2011, 14 pages. |
International Search Report and Written Opinion issued in PCT/US2011/052541, dated Mar. 9, 2012, 22 pages. |
International Search Report and Written Opinion issued in PCT/US2012/055673, mailed Dec. 13, 2012, 10 pages. |
International Search Report and Written Opinion issued in PCT/US2013/037432, mailed Nov. 19, 2013, 17 pages. |
International Search Report and Written Opinion issued in PCT/US2013/057732, mailed Dec. 13, 2013, 11 pages. |
Invitation to Pay Additional Fees and Partial Search Report, dated Aug. 17, 2009, issued in PCT/US2008/085533, 6 pages. |
Invitation to Pay Additional Fees and Partial Search Report, issued in PCT/US2010/024062, mailed May 7, 2010. |
Partial International Search Report issued in PCT/US2011/052541, mailed Dec. 6, 2011, 4 pages. |
Partial International Search Report issued in PCT/US2013/013432, mailed Jul. 17, 2013, 6 pages. |
Partial International Search Report issued in PCT/US2013/037432, mailed Jul. 17, 2013, 6 pages. |
Static Spark Gap Analysis, captured Dec. 24, 2002, [http;//www.richieburnett.co.uk/static.html]. |
International Search Report and Written Opinion issued in PCT/US2013/065517, mailed Dec. 20, 2013, 11 pgs. |
Number | Date | Country | |
---|---|---|---|
20140155972 A1 | Jun 2014 | US |
Number | Date | Country | |
---|---|---|---|
61291556 | Dec 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13767445 | Feb 2013 | US |
Child | 14174358 | US | |
Parent | 12940489 | Nov 2010 | US |
Child | 13767445 | US |